REGN

Nasdaq

REGENERON PHARMACEUTICALS, INC.

Health Care, Biotechnology

$784.36

close 7 Aug 2026

+43.67%

52-week change

$80.75B

market cap

$541.00

$821.11

52-week range

Valuation

Market cap$80.75B

P/E (TTM / 5y avg)19.42x17.91x

Forward P/E (FY2026 / FY2027)14.80x15.56x

PEG (TTM / fwd)7.02—

P/S (TTM)5.20x

P/B2.55x

EV/EBITDA (TTM)18.36x

FCF yield (TTM)4.66%

Cash flow & dividend

FCF (TTM)$3.76B

FCF per share (TTM)$36.52

FCF margin (TTM)24.21%

Dividend yield (indicated / 5y avg)0.48%0.56%

Annualized dividend$3.76

Payout ratio (EPS / FCF)8.74%10.07%

Growth & quality

Revenue YoY, latest Q+16.73%

Diluted EPS YoY, latest Q-4.53%

Operating margin (TTM)24.74%

Net margin (TTM)27.86%

ROE (latest FY)14.41%

Net debt / EBITDA (TTM)-0.11

Interest coverage (TTM)69.37

Price

+25.54%+4.67%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +11.04%10Y CAGR +13.33%

Diluted EPS

5Y CAGR +6.33%10Y CAGR +22.35%

FCF per share

5Y CAGR +16.64%10Y CAGR +20.83%

Operating cash flow

5Y CAGR +13.72%10Y CAGR +14.10%

Free cash flow

5Y CAGR +15.29%10Y CAGR +20.11%

Dividends per share

Payout ratio

FCF payout ratio

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR -1.16%10Y CAGR -0.59%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date26 Oct 2026

EPS estimate$13.70

Revenue estimate$4.34B

Last reported

Date—

EPS——

Revenue——